MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives were To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people, even though on the list of https://manleyo477ovr8.wikiannouncing.com/user